Advanced Search
Disease Phase
Title Drug
Clinical Trials Listing
  • < Previous
  • 1
  • Next >
  • Penn Treatment Trials (11)
  • Penn Non-Treatment Trials (6)
  • Phase 1: Solid Tumor Trials (3)
  • Proton Therapy Trials (1)
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
JWCI-MORD-LM/SL-CLND-1102 A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node III Surgery Not Applicable
GO27826 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF Mutant Melanoma at High Risk for Recurrence III B-Raf Inhibitor vemurafenib
ECOG-E1609 A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon Alpha-2b for Resected High-Risk Melanoma III Immunotherapy interferon alfa-2b; ipilimumab
UPCC 11612 Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma II Chemotherapy, Immunotherapy (Monoclonal Antibody) MK-3475 (Immunotherapy : PD-1 inhibitor)
CA209-064 An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma II Immunotherapy ipilimumab
UPCC 06611 RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma I / II Immunotherapy ipilimumab
INCB 24360-201 A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma I / II Immunotherapy, Signal Transduction Inhibitor ipilimumab; INCB024360
PX-866-007 Phase 1/2 Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) in Patients With BRAF-mutant Cancer Including Advanced Melanoma I / II Signal Transduction Inhibitor vemurafenib; PX-866
P07990 Phase I Study of Single Agent MK-3475 in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma I Signal Transduction Inhibitor MK-3475 (Immunotherapy : PD-1 inhibitor)
CA186-011 A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of BMS-663513 (Anti-CD137) in Subjects With Advanced and/or Metastatic Solid Tumors I Immunotherapy BMS-663513
UPCC-05609 A Phase 1 Dose-Escalation Trial To Evaluate Safety, Tolerability And Immune Pharmacodynamics Of Combined Administration Of Tremelimumab (Blocking Anti-CTLA-4 Antibody) And CP-870,893 (Agonist Anti-CD40 Antibody) In Patients With Metastatic Melanoma I Biological Therapy, Immunotherapy tremelimumab; CP-870,893
Displaying: 1 - 11 of 11 Results
  • < Previous
  • 1
  • Next >